Equibles does not estimate personal net worth.
Get an email with a short summary when Agios Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AGIO alertsThe proxy statement of Agios Pharmaceuticals, Inc. reports total compensation of $2,086,680 for Sarah Gheuens in fiscal 2025, including a base salary of $601,060. Disclosed compensation is on record for 7 fiscal years. Sarah Gheuens has spoken on 1 earnings call and 3 other investor events across 1 company, most recently for Agios Pharmaceuticals, Inc. on July 30, 2026. Agios Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Agios Pharmaceuticals, Inc. includes Brian Goff (CEO and Board Member), Jacqualyn Fouse (CEO and Board Member), David P. Schenkein (Chairman) and 7 others.
“Turning to our pipeline on the next slide, following recent portfolio prioritization decisions, we remain focused on advancing a diversified rare hematology portfolio with opportunities across multiple stages of development.”
“At this year's EHA Congress, Agios is presenting a broad and comprehensive data set for Metapivat across multiple hemolytic anemias, including 10 accepted abstracts and an oral plenary presentation of the Rise Up Phase III trial in sickle cell disease.”
“At this year's EHA Congress, Agios is presenting a broad and comprehensive data set for Metapivat across multiple hemolytic anemias, including 10 accepted abstracts and an oral plenary presentation of the Rise Up Phase III trial in sickle cell disease.”
“So the submission of the SMDA, which means that we indeed have alignment on the confirmatory trial in which we are further looking to demonstrate clinical benefit.”
Proxy statement
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Agios Pharmaceuticals, Inc. (AGIO) | M.D., Ph.D. Chief Medical Officer, Head of Research & Development | $601,060 | $2,086,680 |
| 2024 | Agios Pharmaceuticals, Inc. (AGIO) | M.D., Ph.D. Chief Medical Officer, Head of Research & Development | $583,495 | $2,544,347 |
| 2023 | Agios Pharmaceuticals, Inc. (AGIO) | M.D., Ph.D. Chief Medical Officer, Head of Research & Development | $566,500 | $2,870,159 |
| 2022 | Agios Pharmaceuticals, Inc. (AGIO) | M.D., Ph.D. Chief Medical Officer, Head of Research & Development | $532,500 | $1,846,903 |
| 2021 | Agios Pharmaceuticals, Inc. (AGIO) | M.D., Ph.D. Chief Medical Officer, Head of Research & Development | $437,583 | $1,169,510 |
| 2020 | Agios Pharmaceuticals, Inc. (AGIO) | M.D., Ph.D. Chief Medical Officer, Head of Research & Development | — | — |
| 2019 | Agios Pharmaceuticals, Inc. (AGIO) | M.D., Ph.D. Chief Medical Officer | — | — |
